<h2 dir="ltr">What Are Lentiviral &amp; Vector Systems for CRISPR?</h2>
 Lentiviral vector (LV) systems deliver CRISPR/Cas9 components with the capacity to carry complex transgenes and sustain robust, long-term expression across dividing and non-dividing cell types. Unlike transient transfection, lentiviral transduction integrates the transgene into the host genome, making it the method of choice for generating stable Cas9-expressing cell lines and pooled sgRNA library screens. The right vector system influences gene delivery efficiency, expression control, and experimental success. Select the platform that best fits your research objectives.
&nbsp;
<h2 dir="ltr">What you will find:</h2>
&nbsp;
<ul>
<li dir="ltr" aria-level="1">
Epigenetic Modulator Lentivirus (TET1CD/DNMT3A): Tailored viral platforms created for precise DNA methylation or demethylation to investigate gene control and epigenetic changes at particular sites.
</li>
<li dir="ltr" aria-level="1">
CRISPRa &amp; CRISPRi Delivery Mechanisms (VPR/KRAB): Advanced dCas9 lentiviral vectors designed for strong transcriptional enhancement or repression while preserving the original DNA sequence.
</li>
<li dir="ltr" aria-level="1">
Cas9 Nuclease &amp; Nickase Lentiviruses: Immediately usable viral particles that ensure effective transport of double-strand break or single-strand nicking enzymes for lasting site-directed mutagenesis.
</li>
<li dir="ltr" aria-level="1">
Lentiviral Cloning &amp; Expression Vectors: Adaptable transfection-ready genetic frameworks equipped with C-terminal tags and enhanced promoters for the creation of tailored guide RNA and effector proteins.
</li>
<li dir="ltr" aria-level="1">
Non-Viral Cas9 Vector Options: High-quality plasmid-based systems intended for temporary expression in scenarios where viral incorporation is not needed.
</li>
<li dir="ltr" aria-level="1">
High-Titer Packaging Solutions: Viral preparations safe from endotoxins, enhanced for optimal transduction efficiency in delicate therapeutic candidate evaluation and disease modeling.
</li>
</ul>
<h2 dir="ltr"> How to Choose Lentiviral/Vector CRISPR Systems</h2>
 Packaging Generation Second- and third-generation packaging designs progressively remove viral accessory genes (nef, vif, vpr, vpu) for enhanced biosafety. Third-generation systems split packaging components across two plasmids and eliminate the Tat transactivator, producing replication-incompetent particles suitable for BSL-2 settings. CRISPR-Specific Format Cas9 lentiviral plasmids provide stable Cas9 integration; pre-linearised sgRNA lentiviral plasmids are ready for guide sequence insertion; dox-inducible (Tet-On) Cas9 systems allow temporally controlled editing. Paired Cas9 and sgRNA vectors generate inducible stable editing cell lines. Transient vs. Stable Needs For experiments requiring transient editing without permanent genomic modification, all-in-one or dual-plasmid Cas9/sgRNA transfection systems (lipid-based or electroporation) are appropriate. For stable, heritable expression, lentiviral integration is required. Cell Type Lentiviral vectors transduce both dividing and non-dividing cells, including post-mitotic neurons and macrophages &mdash; applications that gamma-retroviral vectors cannot support. Screening Scale Pooled sgRNA libraries transduced at low MOI enable genome-wide functional screens; stable lentiviral Cas9 cell lines, generated once and banked, provide a consistent starting point for multiple guide RNA screen iterations. 
<h2 dir="ltr"> Specifications Context</h2>
 Lentiviral and vector systems support pooled genome-wide CRISPR knockout screens, stable Cas9 cell line generation, inducible gene editing models, hard-to-transfect primary cell engineering, and CAR-T cell development workflows. Lentiviral plasmids contain LTRs prone to recombination in standard E. coli strains &mdash; recombination-resistant strains such as Stbl3 are recommended for plasmid propagation. Integrase-deficient lentiviral vectors (IDLVs) or RNP electroporation are preferred where insertional mutagenesis risk must be minimised, such as therapeutic cell engineering. For research-scale work where stable integration is the goal, third-generation lentiviral systems remain the standard choice given their established safety record and broad cell-type compatibility across academic and industry labs. Labs new to lentiviral work often start with a well-characterised packaging system and a small pilot transduction before scaling to a full screen or stable line generation campaign.
&nbsp;
Reach out to the professional <a href="https://mbpinc.net/contact-us" style="color: #236fa1;">team at MBP Inc.</a> now to obtain a quote for the perfect Lentivirus system tailored to your research needs.

Vector & Lentivirus Systems

Lentivirus Systems

Restriction Enzyme Analysis of K005

Cas9 Nickase Lentiviral Vector

Unit Quantity

Vector

Note

Shipping Condition

QC - Lot. No. VH7954

Cas9 Nickase Lentivirus

Titer

<h2 dir="ltr">What Are AAV and Adenovirus CRISPR Delivery Systems?</h2>
 AAV and adenovirus-based delivery systems exploit the natural cell-entry machinery of these viruses to deliver Cas9 and guide RNA cargo into cells that resist conventional transfection &mdash; including primary cells, stem cells, neurons, and in vivo tissues. AAV is the most widely used viral vector for CRISPR-based gene editing, valued for high transduction efficiency, low immunogenicity, and an established safety profile in human gene therapy. The right viral delivery system influences transduction efficiency, expression profile, and genome-editing outcomes. AAV and adenoviral vectors offer distinct advantages depending on your research goals.
&nbsp;
<h2 dir="ltr">What you will find:</h2>
&nbsp;
<ul>
<li data-section-id="17k5oh4" data-start="0" data-end="142">Adenoviral Cas9 &amp; Nickase Nucleases: Viral delivery systems for rapid, transient Cas9 or nickase expression without genomic integration.</li>
<li data-section-id="12kolej" data-start="144" data-end="280">AAV6 &amp; AAV8 Viral Vectors: Serotype-specific AAV vectors optimized for transduction of hematopoietic stem cells and liver tissues.</li>
<li data-section-id="81toc4" data-start="282" data-end="412">saCas9 AAV Serotypes (1&ndash;10): Diverse AAV serotypes designed to support targeted cellular tropism across CRISPR applications.</li>
<li data-section-id="18h5j1a" data-start="414" data-end="554">Ampicillin-Selected AAV Vectors: AAV vector backbones containing ampicillin resistance markers for cloning and transformant selection.</li>
<li data-section-id="xfx9g1" data-start="556" data-end="697" data-is-last-node="">High-Titer Viral Particles: Purified viral preparations optimized to maintain genomic integrity and minimize endotoxin-related effects.</li>
</ul>
<h2 dir="ltr"> How to Choose AAV/Adenovirus CRISPR Delivery</h2>
 Genome Capacity Requirements AAV's ~4.7 kb packaging capacity is too small for full-length SpCas9 (~4.2 kb) plus a promoter and guide RNA. Split-vector systems (Cas9 across two AAV particles) or compact Cas9 orthologs such as SaCas9 (~3.2 kb) address this limit. Adenovirus offers 34&ndash;43 kb capacity for larger cargo. Serotype and Tissue Tropism AAV serotypes differ in their ability to transduce specific cell types and tissues, making serotype selection an important part of CRISPR delivery design. The optimal serotype depends on the target tissue, model system, administration route, and experimental goals. MBP offers saCas9 AAV viruses in multiple serotypes (AAV1&ndash;AAV11) to support a range of research applications. Cell Division Status Both AAV and adenovirus transduce dividing and non-dividing cells, making them suitable for primary neurons, hepatocytes, and other post-mitotic populations that resist standard transfection. Immunogenicity Considerations AAV has low immunogenicity and minimal integration risk, supporting widespread pre-clinical and clinical in vivo use. Adenovirus offers higher initial transduction efficiency and larger cargo capacity but generates a stronger immune response, which can limit in vivo utility. Packaging System Helper-free packaging systems eliminate the need for replication-competent helper virus, designed for BSL-2 containment &mdash; though institutional biosafety committee (IBC) approval is required before starting viral vector work. 
<h2 dir="ltr"> Specifications Context</h2>
 AAV and adenoviral CRISPR delivery systems support retinal gene therapy models, CNS editing studies, liver-targeted in vivo CRISPR, muscle cell engineering, primary immune cell editing, iPSC-derived cell modification, and genome-modified animal model generation. Capsid engineering through directed-evolution platforms continues to expand AAV tropism options, including enhanced CNS penetration following systemic delivery, an active area of pre-clinical research relevant to labs planning long-term in vivo programs. All recombinant AAV production and adenoviral vector work requires IBC approval at BSL-2 containment in most jurisdictions; MBP can provide biosafety classification documentation. Product availability reflects MBP's catalogue as of mid-2026. 
&nbsp;
Reach out to the professional <a href="https://mbpinc.net/contact-us" style="color: #236fa1; text-decoration: underline;">team at MBP Inc</a>. now to ask for a quote for a suitable AAV or Adenovirus system for your lab.

AAV/Adenovirus Systems

Cas9 Nuclease Adenovirus

<h2 dir="ltr"> What Are Cas9 Enzymes?</h2>
 Cas9 is the catalytic core of the CRISPR/Cas9 editing system. Sourced from Streptococcus pyogenes (SpCas9) or Staphylococcus aureus (SaCas9), recombinant Cas9 proteins are expressed and purified to high purity for direct use in ribonucleoprotein (RNP) complexes &mdash; currently the most widely recommended format for mammalian cell editing due to rapid activity onset and minimised off-target effects compared to plasmid-based delivery. Genome-editing performance depends on the appropriate nuclease format. Choose the Cas9 enzyme that aligns with your editing strategy.
&nbsp;
<h2 dir="ltr">What you will find:</h2>
&nbsp;
<ul>
<li dir="ltr" aria-level="1">
NLS-Tagged Cas9 and saCas9 Nucleases: Recombinant proteins of high purity designed for quick nuclear localization and strong initiation of double-strand breaks (DSBs) at specific genomic sites.
</li>
<li dir="ltr" aria-level="1">
Precision Cas9 Nickase (H840A): Tailored variants created for dual-nicking approaches to improve genomic stability and notably minimize off-target alterations.
</li>
<li dir="ltr" aria-level="1">
Lyophilized Nuclease Preparations: Nuclease-free, shelf-stable proteins that offer optimal adaptability for reconstitution and high-throughput automated CRISPR-related processes.
</li>
<li dir="ltr" aria-level="1">
Catalytically Inactive Null Mutants: "Dead" Cas9 (dCas9) proteins designed for DNA-binding research and specific epigenetic modification without changing the original sequence.
</li>
<li dir="ltr" aria-level="1">
Cas12a (asCpf1) Nucleases: Alternative CRISPR systems that focus on T-rich PAM sequences to broaden the range of spatial transcriptomics and targetable genomic areas.
</li>
<li dir="ltr" aria-level="1">
GFP-Tagged Cas9 Proteins: Fluorescently marked nucleases developed for real-time assessment of transfection efficacy and visual verification of cellular absorption.
</li>
<li dir="ltr" aria-level="1">
Endotoxin-Free Enzyme Formulations: Highly pure mixtures crucial for preserving cell viability in sensitive lentiviral applications and primary cell modifications.
</li>
</ul>
<h2 dir="ltr"> How to Choose a Cas9 Enzyme</h2>
 PAM Requirement Wild-type SpCas9 recognises any genomic locus flanked by an NGG protospacer adjacent motif (PAM), occurring roughly every 8&ndash;12 bp in mammalian genomes. SaCas9 requires NNGRRT, though engineered PAM variants (KKH, KRH, KRKH) expand targetable space. Off-Target Sensitivity High-fidelity Cas9 variants carry substitutions in the recognition lobe that reduce non-specific DNA contacts, lowering off-target cleavage while maintaining on-target activity comparable to wild-type SpCas9 &mdash; recommended for therapeutic cell engineering and base editing. Editing Mechanism Wild-type SpCas9 generates a blunt double-strand break repaired by NHEJ (indels for knockout) or HDR (precise insertions). Nickase (D10A) cuts only one strand for paired-nick HDR strategies with reduced off-target indels. dCas9 carries mutations in both nuclease domains, enabling CRISPRa/CRISPRi gene regulation without DNA cleavage. AAV Compatibility SaCas9, at approximately 1 kb smaller than SpCas9, fits a complete Cas9 + sgRNA expression cassette within the ~4.7 kb AAV packaging capacity &mdash; enabling single-vector in vivo delivery without split-vector complexity. Storage and Handling Recombinant Cas9 proteins are supplied for stability during shipping and short-term storage at &minus;20 &deg;C or &minus;80 &deg;C. Repeated freeze-thaw cycles reduce activity; aliquoting upon receipt is recommended.
<h2 dir="ltr"> Specifications Context</h2>
 An RNP is a pre-formed complex of recombinant Cas9 protein and sgRNA; once electroporated, it acts immediately and is degraded within hours, reducing off-target cleavage and avoiding immune stimulation associated with plasmid or mRNA delivery.&nbsp;Recombinant Cas9 in RNP format is validated across HEK293, HeLa, iPSCs, T cells, primary neurons, and hepatocytes, though electroporation parameters typically require cell-type-specific optimisation. Product offerings reflect MBP's catalogue as of mid-2026. 
&nbsp;
Reach out to the supportive <a href="https://mbpinc.net/contact-us" style="color: #236fa1;">team at MBP Inc.</a> now to obtain a quotation for the perfect Cas9 enzyme for your study.

ABM